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Introduction
The skeleton is a dynamic organ that normally maintains its mass 
by collateral osteoblast activity despite constant removal of effete 
bone by osteoclasts. Commonly, in states of hormonal deficiency 
and aging, this balance is compromised as resorption supersedes 
formation, resulting in global loss of bone. Fortuitously, available 
and effective osteoporotic therapies are able to enhance systemic 
bone mass and reduce fracture risk in aging individuals and post-
menopausal women.
Inflammatory diseases that affect joints, skin and the gut — 
including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and 
Crohn’s disease — also promote bone loss that is often severe 
(1–3). Inflammation-driven bone degradation affects the axial and 
appendicular skeleton early in life and enhances the risk of frac-
ture. Even when not profound, inflammation increases fracture 
risk, underscoring its skeletal relevance (4, 5).
When inflammation occurs in the vicinity of bone, such as in 
RA, PsA, orthopedic implant–associated osteolysis, and osteomy-
elitis, it induces focal erosion that is often devastating. Although 
major medical achievements have improved the treatment of 
inflammatory arthritides, limitations remain, such as resistance to 
therapy in more than one third of RA and PsA patients and failure 
to restore damaged bone (6). Thus, further understanding of the 
pathogenesis of various forms of focal osteolysis is necessary to 
provide a foundation for their prevention and cure.
Immune cells and their products influence the activities of 
osteoclasts, osteoblasts, and osteocytes to dictate bone mass and 
strength. This relationship of the immune and skeletal systems was 
suggested more than 40 years ago by the discovery that stimulated 
monocytes produce a catabolic, bone resorption–promoting factor 
that was subsequently proven to be IL-1β (7, 8). These observations 
and others, including the discovery of the key osteoclastogenic cyto-
kine, RANKL (9), prompted the discipline of osteoimmunology. 
In consequence, studies of the means by which cytokines such as 
TNF-α, IL-1β, and IL-17 impact bone cells have provided insights into 
the mechanisms of the osteolysis of RA and PsA and improved the 
success of cytokine-inhibiting biological drugs in reducing the crip-
pling peri-articular complications of these diseases. Osteoimmunol-
ogy has also revealed that postmenopausal osteoporosis reflects an 
interplay between estrogen deficiency and immune activation (10). 
Given the excellent reviews on these topics, we will not address the 
role of inflammation in the pathogenesis of systemic bone loss (11).
Osteoclasts are the principal effectors  
of inflammatory osteolysis
While resident mesenchymal and immune cells participate in 
inflammatory bone destruction, the effector cell of focal osteoly-
sis is the osteoclast, the product of myeloid/macrophage precur-
sor fusion (12). In physiological conditions, osteoclast formation 
is dictated by the interaction of RANKL, a member of the TNF 
superfamily, with its receptor RANK (9). Interestingly, whereas 
high-dose RANKL is potently osteoclastogenic, low-dose RANKL 
may actually increase bone formation (13).
RANK activation by RANKL depends upon cytokine-mediated 
trimerization of the receptor in a TNF receptor–associated fac-
tor 6–dependent (TRAF6-dependent) manner (14–16). RANKL/
RANK signaling induces MAP kinases and NF-κB, eventuating in 
the activation and expression of NFATc1, the key osteoclasto genic 
transcription factor (17–20). Elevation of RANKL abundance, 
which is typically the crucial event regulating bone resorption, is 
negatively regulated by osteoprotegerin (OPG) (21–23), a decoy 
receptor with a higher affinity for the osteoclastogenic cytokine 
than that of RANK; thus, RANKL binding to OPG effectively lim-
its osteoclastogenesis (9, 15). In fact, loss-of-function OPG muta-
tions prompt a severe generalized osteolytic disorder known as 
juvenile Paget’s disease (24). Macrophage colony-stimulating fac-
tor (M-CSF) is also essential for osteoclast formation, exerting its 
effects by signaling via its receptor, C-FMS (25).
The magnitude of bone degradation depends upon both the num-
ber of osteoclasts and their individual resorptive capacity. As stated 
above, physiological osteoclast abundance is dictated principally 
by RANKL, M-CSF, and OPG, which are modulated by cytokines 
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that recruits osteoclasts, the direct mediators of the osteolytic 
component of the disease (Figure 1). Thus, anti-osteolytic strate-
gies include inflammatory cytokine inhibition, such as TNF-α and 
IL-6 receptor blockade, both of which indirectly diminish osteo-
clastogenesis, as well as direct inhibition of osteoclast formation 
by agents such as denosumab, a humanized anti-RANKL anti-
body (34). The fact that NF-κB mediates both inflammation and 
osteoclast formation suggests its candidacy as a therapeutic tar-
get in inflammatory osteolysis (35–38). While an NF-κB–focused 
strategy may be compromised by the broad biological necessity of 
the transcriptional complex, systemic administration of peptide- 
siRNA nanocomplexes targeting NF-κB subunit p65 dramatical-
ly suppresses the inflammatory and bone-erosive components of 
experimental arthritis without apparent off-target effects (39).
A number of inflammatory cytokines may contribute to the 
periarticular bone loss of RA, but the most significant is TNF-α. 
Macrophages and T cells express TNF-α in the arthritic synovi-
al tissue as a membrane-residing protein that does not promote 
osteoclast formation until it is cleaved to its soluble form (40). 
Like RANKL, TNF-α exerts its biological effects by clustering 
and trimerizing three monomeric receptors (41). In fact, TNF-α 
activates two known receptor complexes, namely TNF receptor 
type 1 (TNFR1) and type 2 (TNFR2), and each prompts different 
intracellular events. TNFR1, which is principally stimulated by 
soluble TNF-α, transmits proinflammatory signals and synergizes 
with RANK to promote osteoclastogenesis (42). Signals induced 
by TNFR2, which largely recognizes membrane-residing TNF-α, 
are pro-immunogenic and anti-inflammatory (43). Thus, TNFR1 
is responsible for the crippling effects of RA, PsA, and other forms 
of focal osteolysis, such as that complicating orthopedic implanta-
tion (44, 45). In fact, there is compelling evidence that complica-
in states of inflammatory bone disease. Whereas RANKL increases 
osteoclast number by promoting precursor differentiation, M-CSF 
does so by enhancing proliferation of progenitors and restricting 
apoptosis. The capacity of the individual osteoclast to resorb bone, 
on the other hand, is largely a product of cytoskeletal organization. 
The resorptive machinery polarizes toward the cell-bone interface, 
enabling its transport into an isolated resorptive microenvironment 
in which degradation of the mineralized and organic components of 
the skeleton occurs sequentially (26). This process involves fusion of 
cytoplasmic vesicles containing matrix-degrading molecules to the 
bone-apposed plasma membrane. Fusion of these lysosome- derived 
vesicles to the plasma membrane generates the ruffled border, the 
unique resorptive organelle of the osteoclast, which transports min-
eral-mobilizing HCl and organic matrix–degrading cathepsin K into 
the resorptive space (27–31). Polarization of resorptive molecule–
containing vesicles is initiated by signals derived from mineralized 
matrix via cell surface integrins, particularly αvβ3 (32). In addition 
to their role in osteoclast formation, both RANKL and M-CSF pro-
foundly enhance bone resorption by the mature osteoclast via 
canonical organization of its cytoskeleton (33). Given the abundance 
of RANKL and M-CSF in states of inflammatory osteolysis, it is likely 
that the robust bone destruction reflects both increased numbers 
of osteoclasts and enhanced resorptive capacity of the mature cell. 
Thus, understanding the means by which inflammation destroys 
bone must be viewed in the context of interplay between cytokines 
that regulate these two critical osteoclastogenic factors.
Cytokine-induced focal osteolysis in RA
In many circumstances, osteolysis occurs adjacent to inflamma-
tion, such as in arthritic periarticular tissue. The secreted products 
of infiltrating immune cells perpetuate the inflammatory response 
Figure 1. Cytokines are key regulators of inflam-
matory osteolysis. Despite differences in the 
pathogenesis of various inflammatory diseases, 
proximal regulators of osteoclastogenesis are the 
same, although the “cocktail” of these factors 
may differ. These factors may act at one or more 
aspects of the osteoclastogenic pathway from 
osteoclast generation to activation of resorption. 
While the homeostatic actions of pro-osteoclast 
factors (green) are balanced by those that are 
anti-osteoclast (red), pro-osteoclast factors 
dominate in inflammatory conditions, thereby 
increasing osteoclast number and enhancing the 
cell’s capacity to resorb bone. Some factors, such 
as IFN-γ, have context-dependent effects on 
osteoclasts (see text). HSC, hematopoietic stem 
cell; OC, osteoclast.
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potently activates the canonical RelA pathway, which inhibits 
osteoblast differentiation, and therefore could contribute to the 
uncoupling of RA bone resorption from formation (63). However, 
this conclusion is controversial, as others report that NF-κB posi-
tively affects osteogenesis (64). Given the central role of Wnt sig-
naling in osteoblast differentiation, the failure of RA focal osteoly-
sis to heal is perhaps more likely due to the osteogenic-suppressive 
properties of TNF-α mediated through its induction of dickkopf-1 
(DKK-1), a potent inhibitor of Wnt activation (65–67). Interestingly, 
in contrast to TNF-α arrest, which suppresses osteoclastogenesis 
but does not increase bone formation, blockade of DKK-1 does 
both, thus repairing erosive lesions (66).
IL-1β, which is abundant in RA pannus and other inflamed 
tissues, induces and partners with TNF-α to promote inflamma-
tory osteolysis (58). In this circumstance, TNF-α enhances the 
synthesis of IL-1β by synovial fibroblasts (68) and macrophages. 
IL-1β, in turn, stimulates expression of RANKL and RANK as well 
as its own receptor. In fact, IL-1β mediates approximately 50% 
of TNF-α–induced osteoclastogenesis. The interdependency of 
TNF-α, RANKL, and IL-1β lends credence to the concept that com-
bined blockade more effectively prevents inflammatory bone loss 
than single cytokine inhibition (69).
Autoantibody-induced focal osteolysis in RA
While molecular effectors of innate immunity have been long rec-
ognized as mediators of bone loss, until recently little was known 
about the role of B cell–produced immunoglobulins as the key 
molecular effectors of adaptive immunity in skeletal degrada-
tion. Clinical observations suggested that rheumatoid factor, an 
immune complex induced by an IgM autoantibody against the Fc 
portion of IgG, and anti-citrullinated protein autoantibodies are 
potent risk factors for focal osteolysis in RA. Anti-citrullinated 
vimentin antibodies directly stimulate myeloid lineage cells to 
produce TNF-α and IL-8, which in turn induce osteoclastogene-
sis (70, 71). Furthermore, individuals with such antibodies but 
no signs of RA develop skeletal abnormalities, indicating a direct 
effect on bone (72). Immune complexes such as rheumatoid fac-
tors also stimulate osteoclast formation and function by cross-
linking Fc receptors and activating SYK (73, 74). Importantly, 
anti-citrullinated protein autoantibodies and rheumatoid factors 
additively trigger bone loss (75).
IL-17 and focal osteolysis in PsA
In contrast to RA, in which TNF-α predominates, PsA is charac-
terized by robust activation of the IL-23/IL-17 axis (76). IL-17 is 
produced by Th17 and innate lymphoid (ILC3) cells exposed to 
IL-23. IL-17–expressing T cells infiltrate the skin and the joints 
of psoriatic patients and likely drive their clinical manifesta-
tions. Th17 cells synthesize IL-17 and express RANKL, both of 
which directly induce osteoclast differentiation (77, 78). Addi-
tionally, IL-17 potentiates RANKL’s osteoclastogenic capacity 
by upregulating RANK on osteoclast precursor cells (79). IL-17 
also indirectly promotes bone destruction by inducing synovial 
fibroblasts and macrophages, respectively, to express TNF-α, 
IL-1, and IL-6 (80, 81). In fact, inducing osteolytic cytokines, 
especially TNF-α, in these cells, may be the principal means by 
which IL-17 causes arthritic osteolysis. In contrast to IL-17, IL-23, 
tions of anti–TNF-α therapy substantially reflect a failure to distin-
guish TNFR1 and TNFR2 (46, 47). Recently developed strategies, 
including manipulation of affinities for the two receptors to pro-
mote selective binding and thus inhibition of TNFR1 while sparing 
TNFR2, may attenuate the problematic properties of TNF-α while 
maintaining those that are salutary (48).
TNF-α potently stimulates osteoclast formation, but whether 
it does so independently of RANKL is controversial. Administra-
tion of TNF-α to RANKL-deficient mice fails to induce meaningful 
formation of the bone-resorptive cell (49), but TGF-β may substi-
tute for RANKL in certain circumstances (50). Challenging the 
concept that RANKL-independent osteoclast formation may par-
ticipate in inflammatory bone loss is the finding that Rankl-knock-
out mice are protected from arthritic bone erosions (51). On the 
other hand, deletion of RBP-J, a transcription factor that inhibits 
osteoclast formation in the context of inflammation, enables 
RANKL-independent, TNF-α–induced, but not physiological, 
osteoclastogenesis (52). Similarly, absence of TRAF3 or NF-κB2/
p100 alleviates inhibition of osteoclast formation in the context 
of TNF stimulation (53). Furthermore, combined TNF-α and 
IL-6 promote osteoclast formation and bone erosions in RANK- 
depleted myeloid precursors. Osteoclasts are also present, though 
diminished, in arthritic mice with inducible RANK deficiency 
(54). It therefore appears that in certain circumstances TNF-α may 
promote osteoclast formation in the absence of RANKL, but the 
biological significance of this event is yet to be defined. It is also 
clear that TNF-α and RANKL are synergistic, and the inflamma-
tory cytokine needs only minimal amounts of RANKL to directly 
stimulate macrophages to differentiate into osteoclasts (55, 56). 
The osteoclast-inducing properties of relatively low quantities 
of TNF-α are largely the product of enhanced RANKL expres-
sion by mesenchymal cells, such as those residing in pannus, the 
inflamed and hypertrophied synovium of arthritic joints (57). As 
TNF-α abundance increases, its osteoclastogenic effects progres-
sively reflect direct stimulation of myeloid precursors, while the 
contribution made by increasing RANKL diminishes (55, 57, 58). 
Thus, osteolysis accompanying relatively modest elevations of 
ambient TNF-α depends upon responsive stromal cells. Alterna-
tively, in states of severe periarticular inflammation, TNF-α may 
fully exert its bone-erosive effects by directly promoting differ-
entiation of osteoclast precursors and their expression of RANK 
receptor independent of cytokine-responsive stromal cells and T 
lymphocytes (57). The capacity of TNF-α to prompt RANK expres-
sion and osteoclast formation is dependent upon its induction of 
M-CSF by stromal cells (59), which increases osteoclast precursor 
abundance (60). Importantly, antibody blockade of the M-CSF 
receptor C-FMS completely arrests TNF-α–induced osteolysis, 
with minimal effects on macrophage number. C-FMS blockade 
also limited local and systemic resorption in two mouse models 
of inflammatory arthritis (61). Thus, M-CSF and its receptor are 
candidate therapeutic targets in inflammatory osteolysis.
Physiological bone remodeling is characterized by a “cou-
pling” of osteoclast and osteoblast activity, and the same holds 
true in pathological conditions such as PsA (45). In contrast, the 
robust osteoclastogenesis of RA is accompanied by suppressed 
bone formation, and thus its erosive lesions exhibit limited osteo-
blast activity even in face of therapeutic intervention (62). TNF-α 
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and limit bone loss in mice following RANKL injection or ovariec-
tomy (92–94). Whether the osteoclast-suppressive properties of 
Tregs or Tcregs are compromised in inflamed joints is unknown.
Understanding the role of Th1 cells in the skeleton has been 
more complex than exploring Tregs. Activated Th1 cells were orig-
inally considered pro-osteoclastogenic, as they express RANKL 
(95). Th1 cells, however, actually suppress osteoclast formation 
in vitro, postulated to be via co-production of IFN-γ, challenging 
their role in RA-associated focal osteolysis (18, 78). Surprisingly, 
however, human CD4+IFN-γ+ T but not CD4+IFN-γ– T cells express 
RANKL and thus promote osteoclastogenesis (96). Importantly, 
CD4+IFN-γ+ T cells are selectively increased in the circulation of 
RA patients and IFN-γ stimulates osteoclast formation and bone 
loss in vivo (96, 97). Thus, Th1-produced IFN-γ appears to directly 
inhibit and indirectly stimulate osteoclast formation, with the lat-
ter predominating in vivo.
Skeletal changes associated with excessive 
inflammasome activation
Inflammasomes are intracellular protein complexes expressed 
mainly by myeloid cells, including osteoclasts (98, 99), but also 
develop in osteoblasts and chondrocytes (98, 100, 101). They pro-
tect against infections upon recognition of microbial structures 
known as pathogen-associated molecular patterns (PAMPs) (102). 
Inflammasomes also restore tissue integrity after injury by sensing 
danger-associated molecular patterns (DAMPs) from damaged 
cells (103–105). They function primarily by converting pro–IL-1β 
and pro–IL-18 to their biologically active forms (103).
Inflammasomes are assembled by nucleotide-binding oligo-
merization domain, leucine-rich repeat–containing proteins 
(NLRP1, NLRP3, NLRC4, NLRP6, and NLRP12), absent in mela-
noma 2–like (AIM 2-like) receptors (known as ALRs), or pyrin (ref. 
103 and Figure 2). These proteins act as receptors for PAMP- and 
DAMP-associated molecular patterns. Ligand recognition enables 
the recruitment and oligomerization of apoptosis-associated 
speck-like protein containing a caspase activation recruitment 
domain (CARD). Complex assembly activates caspase 1, which 
proteolytically processes pro–IL-1β and pro–IL-18. The NLRP3 
inflammasome signaling cascade cleaves poly(ADP-ribose) poly-
merase 1 (PARP1) (106–108).
Owing to its robust activation by monosodium urate crystals, 
the NLRP3 inflammasome plays a key role in gout (109). The 
NLRP3 inflammasome is also activated in RA synovium, consis-
tent with increased IL-1β secretion (110, 111). TNF-α stimulates 
IL-1β expression in vitro, suggesting the latter cytokine may drive 
pro–IL-1β transcription in RA. Although TNF-α and IL-1β regulate 
each other’s expression and osteoclastogenic properties (58), the 
superior efficacy of TNF-α inhibitors in RA relative to those that 
block IL-1 is consistent with the apical role of TNF-α in generating 
focal osteolysis in this disease.
As stated above, inflammasomes also promote cleavage of 
PARP1 (106–108). While it has yet to be studied in the context 
of RA, PARP1 proteolysis occurs during osteoclastogenesis (98, 
99, 112, 113). A proteolytically stable PARP1 mutant antagonizes 
osteoclastogenesis, whereas PARP1 deficiency enhances this pro-
cess (107, 114), indicating that PARP1 negatively regulates osteo-
clast differentiation.
the essential inducer of Th17 differentiation, does not directly 
promote osteoclast formation. The deleterious effects of IL-17 
on bone also reflect suppressed osteogenesis via downregulation 
of Wnt and BMP pathways (12, 82).
Approximately 90% of PsA patients develop bone erosions 
that correlate with the magnitude of joint destruction, establishing 
a pathogenic role of the osteoclast. In contrast to RA, whose bone 
destructive complications are exclusively resorptive, PsA is char-
acterized by not only robust bone resorption but also exuberant 
osteogenesis, particularly in regions of attachment of ligaments 
to bone (entheses), which can eventuate in ankyloses (83). While 
RA is exclusively characterized by synovial inflammation, patients 
with PsA also develop inflamed entheses that may reflect IL-23 
and IL-17 activation. Although inflammation is a prerequisite for 
new bone formation at entheseal sites, IL-17 is unlikely the respon-
sible factor, as it suppresses rather than promotes osteogenesis.
Immunoregulatory mechanisms inhibiting focal 
arthritic osteolysis
Macrophages are central to the pathogenesis of focal osteolysis, as 
they are a principal source of inflammatory cytokines and can dif-
ferentiate into osteoclasts. In fact, the abundance of macrophages 
in pannus parallels disease severity (84). While the osteoclast is a 
macrophage lineage cell, its precise origin remains controversial 
and it is likely influenced by specific environmental circumstanc-
es. This is particularly true regarding the relationship of osteoclasts 
to classically activated, proinflammatory M1 and alternatively 
activated, immunoregulatory M2 macrophages. Assumption of 
the M2 phenotype typically requires IL-4 and IL-13, which inhibit 
osteoclast formation and induce myeloid progenitors to develop 
into non-bone-resorbing polykaryons (85). IL-4 and IL-13 are the 
products of Th2 lymphocytes and eosinophils, respectively. These 
cells suppress inflammatory arthritis and hence its osteolytic con-
sequences (86). TNF-α, which promotes osteoclast formation, 
blunts polarization to the M2 phenotype directly and by arrest-
ing production of IL-13 by eosinophils that are present in arthritic 
joints (86, 87). While these observations suggest that osteoclasts 
are not derived from alternatively activated M2 macrophages, 
inflammatory arthritis in mice recruits osteoclast precursors with 
features of both M1 and M2 cells (88). Hence, differentiation of a 
monocytic precursor into osteoclasts may essentially depend on 
the cytokine micro-milieu to which the cell is exposed, thus allow-
ing a modicum of plasticity in monocyte differentiation.
In addition to stimulating resorption, immune cells may 
retard osteoclast formation and bone loss. For example, CD4+ 
FoxP3+ Tregs are potent inhibitors of osteoclast differentiation, 
exerting their effects by cell contact (89). The anti-resorptive 
capacity of Tregs reflects their anti-inflammatory properties. They 
also directly block osteoclast formation by liganding CD80/CD80 
surface receptors with CTLA4, thereby inducing indoleamine 
2,3-deoxygenase (IDO) (90). In inflammatory conditions, howev-
er, the immune-suppressive capacity of Tregs is compromised by 
proinflammatory cytokines, which promote targeted dephosphor-
ylation of FoxP3 (91). A second population of Tregs that express 
CD8, known as Tcregs, is directly induced via interaction with 
osteoclasts (92). These Tcregs inhibit the resorptive activity of 
osteoclasts, rather than inhibiting their differentiation in vitro, 
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Additionally, mice harboring mutant MEFV establish that the 
pyrin inflammasome is proinflammatory and causes massive 
cartilage and bone erosion (134).
Chronic recurrent multifocal osteomyelitis (CRMO) is an auto-
inflammatory osteolytic disorder. Anti-inflammatory cytokines 
(e.g., IL-10) are diminished, whereas their proinflammatory coun-
terparts (e.g., IL-1β, IL-6, and TNF-α) are increased. This imbal-
ance presumably reflects NLRP3 inflammasome hyperactivation 
and causes exaggerated osteoclastogenesis (135). Immunohisto-
chemical staining of bone of CRMO patients shows that the NLRP3 
inflammasome is increased in osteoclasts (136). Supporting the 
role of cytokines in bone loss during CRMO, TNF-α or IL-1 block-
ers are efficacious (135). Mice harboring a spontaneous missense 
mutation in the proline-serine-threonine phosphatase-interacting 
protein 2 (Pstpip2) gene, which abolishes protein expression, devel-
op a phenotype reminiscent of CRMO, with enhanced osteoclas-
togenesis and bone resorption (137). These mutant mice overpro-
duce IL-1β due to combined and redundant actions of the NLRP3 
inflammasome and caspase 8 (138–140), suggesting that inflam-
masome-independent IL-1β release may occur in some situations.
Pathogenesis of periprosthetic osteolysis
Periprosthetic osteolysis is the most significant long-term compli-
cation of total hip replacement. Prosthetic-wear particles activate 
innate immune responses, causing excessive bone resorption and, 
Inflammasome mutations may prompt stimulus-indepen-
dent activation and are the cause of cryopyrin-associated peri-
odic syndromes (CAPS). Neonatal-onset multisystem inflam-
matory disease (NOMID), the most severe CAPS, is attended by 
bone loss and skeletal deformation (101, 115–118). IL-1–blocking 
agents have limited efficacy against NOMID skeletal lesions, 
while other symptoms related to systemic inflammation are rap-
idly resolved (119–122). While the human disease is phenocopied 
in mouse models with global NOMID mutation (98, 123), mice 
bearing the mutation only in osteoclasts lack systemic inflamma-
tion but have severe osteoporosis (99), indicating a cell-autono-
mous role in the bone-resorptive cell.
In humans, gain-of-function mutations in NLRC4 cause 
a disorder reminiscent of macrophage activation syndrome 
(MAS) (124–127), a life-threatening complication of systemic 
juvenile idiopathic arthritis (JIA). JIA responds to IL-1 blockers 
(128, 129), indicating the inflammasome-activated cytokine 
participates in this osteolytic disorder. Consistent with the 
human phenotype, transgenic mice expressing constitutively 
active NLRC4 develop inflammatory arthritis (130). Similarly, 
activating mutations of MEFV, encoding pyrin, cause familial 
Mediterranean fever (FMF), which is characterized by exces-
sive IL-1β that drives autoinflammation associated with arthri-
tis and bone loss (131, 132). The efficacy of IL-1 blockers under-
scores the pathogenic action of this cytokine in FMF (133). 
Figure 2. The inflammasomes in osteolysis. 
Cytokines such as TNF induce the expression 
of pro–IL-1β, which lacks the signal peptide for 
secretion. Recognition of damage- or pathogen- 
associated molecular patterns (DAMPs or 
PAMPs) by the receptor/sensor component of 
the inflammasome (e.g., NLRP3, NLRC4), or 
activating mutations of some of these receptors, 
leads to the assembly of the inflammasome, a 
protein complex containing the receptor, apop-
tosis-associated speck-like protein containing 
a CARD (ASC) and caspase 1. Once assembled, 
this active complex cleaves pro–IL-1β into active 
IL-1β and triggers cascades that lead to PARP1 
cleavage into p89 and p24 fragments. In precur-
sors sensing DAMPs or PAMPs, cleaved PARP1 
and autocrine effects of IL-1β, acting through 
IL-1R, promote maturation of osteoclasts into 
bone-resorbing cells. Secreted IL-1β can also act 
in a paracrine manner to increase bone resorption 
by nearby osteoclasts. Dashed arrows indicate 
multiple steps.
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ultimately, implant failure (141, 142). The prevalence of myeloid 
cell responses indicates that the NLRP3 inflammasome likely par-
ticipates in prosthetic loosening, implicating crystalline particles 
in the pathogenesis of NLRP3-mediated diseases. Furthermore, 
calvarial bone resorption that is induced by polymethylmethacry-
late (PMMA) particles is reduced in the absence of NLRP3 (143). 
The size and shape of metal alloys affect the amplitude of the 
inflammasome response (144). Plastic components of the pros-
theses also activate the inflammasome. Phagocytosis-enhanced 
production of reactive oxygen species and rupture of phagosomes, 
which release cathepsins in the cytoplasm, are the presumed 
mechanisms of NLRP3 inflammasome activation by particles. 
On the other hand, prosthetic particles generate priming signals 
through TLRs that induce expression of pro–IL-1β and NLRP3 
(145, 146). The NLRP3 inflammasome, however, appears to super-
sede TLR4 signaling in prosthetic-wear particle-induced osteoly-
sis (147). On the other hand, the non-NLR inflammasome AIM2 
and not NLRP3 may mediate the acute phase of PMMA-induced 
foreign body responses (148).
Infection-associated osteolysis
Immune activation during infection causes profound local bone 
loss. Although the term may refer to any instance of bone inflam-
mation, osteomyelitis (OM) is primarily used to describe the 
infection-induced form of disease whose progression is the result 
of interplay among pathogens, the cellular and matrix constitu-
ents of bone, and the immune system. Bacteria may cause bone 
necrosis through direct killing of osteoblasts, but the inflammato-
ry response is likely the major event by which infection induces 
osteoclastogenesis and bone degradation. The most frequently 
identified microorganism in OM is Staphylococcus aureus, which 
is seeded into bone through both hematogenous and direct (e.g., 
trauma, implant) routes in children and adults (149).
Bacterial products of Staphylococcus aureus, which grows pri-
marily in the extracellular bone microenvironment and forms 
biofilms, induce an inflammatory response. Factors released by 
cells adjacent to bacteria include TNF-α, IL-1β, IL-6, IFN-γ, and 
IL-12 as well as the chemokines CCL3 (also known as MIP1α), 
CXCL1, CXCL2 (also known as MIP2α), and CXCL8 (150–154). 
Further linking mechanisms of bone loss in infectious and 
non-infectious inflammatory states, the NLRP3 inflammasome 
is implicated in the response of innate immune cells to Staphylo-
coccus aureus infection. Hemolysins, bacterial lipoproteins, and 
Panton-Valentine leukocidin from Staphylococcus aureus are all 
activators of NLRP3 capable of inducing IL-1β release (155–157). 
In addition to the caspase 1–mediated IL-1β processing event, 
NLRP3 activation induces expression of a variety of cytokines 
in an NF-κB–dependent, caspase 1–independent fashion (158). 
As discussed above, although individual inflammasome factors 
may inhibit osteoclast formation or function, combined release 
is highly osteolytic (151, 159, 160).
In addition to mediating osteolysis via activation of immune 
cells, Staphylococcus aureus directly affects osteoblasts. Staphy-
lococcal protein A binds to and activates TNFR1 on osteoblasts, 
thereby stimulating NF-κB and promoting IL-6 secretion (161). 
The cell wall component peptidoglycan stimulates TLR2 in a 
NOD2-dependent manner, thereby inducing RANKL expression 
by osteoblasts. Concordant OPG remains unchanged (159, 162, 
163) or decreases (164), contributing to osteoclast recruitment 
and osteolysis. Bone loss likely also occurs through reduced osteo-
blast viability as well as reduced activity induced by substances 
released from staphylococcal biofilms (163, 164).
Alveolar bone loss due to periodontitis is another frequent 
form of infection-mediated inflammatory osteolysis. In this con-
text, the most common pathogen is Porphyromonas gingivalis, 
although the human disease is likely polymicrobial, as the oral 
cavity is not a sterile site (165). Alveolar bone loss elicited by Por-
phyromonas gingivalis shares many features of lysis attending OM. 
Cytokine release (166) as well as induction of RANKL downstream 
of TLR2 and NOD2 are the prominent pathways leading to osteo-
clast activation in periodontitis (167, 168). IL-17 is also markedly 
increased in periodontitis and appears to be an important factor in 
both inflammation and osteolysis of the periodontal tissue (169). 
Porphyromonas gingivalis also releases cysteine proteases called 
gingipains, which do not directly induce osteoclastogenesis (170) 
but may act via differential degradation of osteoclast-modulatory 
cytokines, including OPG (171).
Therapeutic perspective
In the not-too-distant past, many patients with RA or PsA were inca-
pacitated because of focal osteolysis, which destroyed periarticular 
bone. Insights gained into the pathogenesis of inflammatory osteol-
ysis, and in particular the interplay of the immune and skeletal sys-
tems, has led to substantial therapeutic progress. RANKL inhibition 
by denosumab, for example, arrests progression of arthritic osteoly-
sis, supporting the concept that stimulated osteoclastogenesis is the 
essential event in inflammatory bone loss (172). However, RANKL 
inhibition, per se, has no intrinsic anti-inflammatory properties and 
therefore must be accompanied by anti-inflammatory agents in 
these disorders (172). All current cytokine inhibitors approved for 
the treatment of inflammatory diseases, which include compounds 
specifically targeting IL-1, IL-6R, IL-17, IL-12/23, and in particular 
TNF-α, limit osteolysis (173–175). The efficacy of TNF-α inhibitors 
appears to reflect combined anti-inflammatory properties and direct 
suppression of bone-resorbing osteoclasts. IL-6R inhibitors, which 
are used exclusively to treat RA, and IL-12/23 and IL-17 blocking 
agents, predominantly employed in psoriatic arthritis, exert similar 
bone-protective effects. The impressive skeletal-sparing properties 
of IL-1 blockers are surprising, as these drugs minimally diminish 
the articular inflammation of RA, supporting the concept that the 
cytokine’s primary effect, in the disease, is direct osteoclast recruit-
ment and activation (176). Clinically, IL-1 inhibitors may have their 
primary bone-protective role in crystal arthropathies such as gout, 
where IL-1β plays a dominant role as an inflammatory cytokine 
(177). A small molecule inhibitor of the NLRP3 inflammasome has 
shown efficacy in rodent disease models (178), thus providing proof 
of concept that pharmacologic inhibition of this inflammasome is a 
viable therapeutic strategy. However, there is no report on NLRP3 
inhibitors in clinical development. Drugs interfering with adaptive 
immune response, particularly T cell activation, also regulate bone 
resorption. CTLA4, for instance, which retards T cell activation and 
is effective in RA, binds osteoclast precursors and arrests their dif-
ferentiation (179). The anti-osteoclastogenic properties of Tregs are 
mediated by CTLA4, which these cells constitutively express (179).
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Since infection-induced osteolysis is primarily the result of the 
host response rather than the direct action of pathogens, blockade 
of cytokines and/or RANKL could be a useful adjunct to debride-
ment and antibiotic therapy. RANKL blockade has been success-
ful in animal models of periodontitis (180–182). Patients treated 
with anti–TNF-α therapy for other disorders have also shown some 
improvement in alveolar bone loss (183).
In summary, while the clinical consequences of skeletal 
inflammation have long been appreciated, recent discoveries 
of immune pathways controlling bone homeostasis have added 
greatly to our understanding as to how these pathological events 
occur. Inflammatory cytokines, autoantibodies, and DAMPs/
PAMPs induce osteoclast differentiation and osteolysis in auto-
inflammatory, autoimmune, and infectious diseases. These dis-
coveries prompted therapeutic interventions, such as cytokine 
blockers, which selectively disrupt the detrimental skeletal effects 
of chronic immune activation and inflammation, thereby limiting 
their associated bone loss. Further examination of immune path-
ways will likely lead to additional approaches to the treatment of 
inflammatory osteolysis.
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